Arrowhead Pharmaceuticals completed a refinancing of its existing Six Street credit facility, lowering borrowing costs to 5.50% SOFR and extending the maturity to 2031 while eliminating mandatory prepayments.
Arrowhead Pharmaceuticals completed a refinancing of its existing Six Street credit facility, lowering borrowing costs to 5.50% SOFR and extending the maturity to 2031 while eliminating mandatory prepayments.